U.S. markets close in 2 hours 37 minutes
  • S&P 500

    4,146.36
    -42.07 (-1.00%)
     
  • Dow 30

    34,224.78
    -518.04 (-1.49%)
     
  • Nasdaq

    13,374.73
    -27.12 (-0.20%)
     
  • Russell 2000

    2,199.47
    -13.23 (-0.60%)
     
  • Crude Oil

    65.19
    +0.27 (+0.42%)
     
  • Gold

    1,834.40
    -3.20 (-0.17%)
     
  • Silver

    27.65
    +0.15 (+0.56%)
     
  • EUR/USD

    1.2161
    +0.0027 (+0.22%)
     
  • 10-Yr Bond

    1.6270
    +0.0250 (+1.56%)
     
  • GBP/USD

    1.4156
    +0.0035 (+0.25%)
     
  • USD/JPY

    108.5790
    -0.2620 (-0.24%)
     
  • BTC-USD

    56,233.79
    -1,266.39 (-2.20%)
     
  • CMC Crypto 200

    1,504.02
    +1,261.34 (+519.76%)
     
  • FTSE 100

    6,947.99
    -175.69 (-2.47%)
     
  • Nikkei 225

    28,608.59
    -909.71 (-3.08%)
     

Viracta Therapeutics to Participate at H.C. Wainwright Global Life Sciences Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

SAN DIEGO, March 3, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that Viracta will participate at the H.C. Wainwright Global Life Sciences Conference, being held March 9-10, 2021. A pre-recorded presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7 a.m. ET on March 9, 2021. Viracta's management team will also be available for one-on-one investor meetings at the conference.

About Viracta Therapeutics, Inc.

Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphoma. Viracta is pursuing application of this inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.

For additional information please visit www.viracta.com.

Investor Relations Contact:

Company Contact:



Joyce Allaire

Dan Chevallard

LifeSci Advisors

Chief Financial Officer

jallaire@lifesciadvisors.com

dchevallard@viracta.com

(212) 915-2569

(858) 771-4193

Viracta Therapeutics, Inc. Logo (PRNewsfoto/Viracta Therapeutics, Inc.)
Viracta Therapeutics, Inc. Logo (PRNewsfoto/Viracta Therapeutics, Inc.)
Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/viracta-therapeutics-to-participate-at-hc-wainwright-global-life-sciences-conference-301239433.html

SOURCE Viracta